Clover Corporation Limited (CLV) AI Stock Analysis

• Market Cap: AU$93.52M
• Dividend Yield: 2.73%
• Average Volume (3M): 68.30K
• Price to Earnings (P/E): 20.7
• Beta (1Y): -0.36
• Revenue Growth: 15.48%
• EPS Growth: 135.65%
• Country: AU
• Employees: 60
• Sector: Industrials
• Sector Strength: 78
• Industry: Packaged Foods
• EPS (TTM): 0.01
• Shares Outstanding: 166,999,340
• 10 Day Avg. Volume: 65,306
• 30 Day Avg. Volume: 68,297
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.55
• Price Target Upside: 0.00%
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 69 Neutral
• Price Target: AU$0.50 ▼(-9.09% Downside)

Clover Corporation Limited's overall stock score is driven by a strong balance sheet and solid cash flow amid declining revenue and profitability. Technically, the stock shows positive trends, although nearing overbought levels. Valuation is reasonable with a modest dividend yield. The absence of earnings call data and notable corporate events limits insights into future strategies and market reactions.

Clover Corporation Limited Business Overview & Revenue Model

Company Description

Clover Corporation Limited refines and sells natural oils in Australia, New Zealand, Asia, Europe, and the Americas. It also engages in the production of encapsulated products; and research and product development of functional food and infant nutrition ingredients. In addition, the company offers Nu-Mega Hi docosahexaenoic tuna oils for use in infant formula and pharmaceutical products; Ocean Gold refined tuna oils; Nu-Mega Driphorm powders that are used in a range of infant formula, follow-on formula, growing up milks, and food applications; and Nu-Mega Driphorm HA for non-dairy applications. Further, it provides products in the areas of active living-immune system and sports, healthy living–brain and heart, and starting out-infant and child. The company was incorporated in 1988 and is headquartered in Altona North, Australia.

How the Company Makes Money

Clover Corporation Limited generates revenue primarily through the sale of its proprietary encapsulated omega-3 and other bioactive ingredient products. These products are sold to manufacturers in the food, beverage, and supplement industries, which incorporate them into their consumer products. The company's key revenue streams include direct product sales, licensing of its encapsulation technology, and collaborative partnerships with leading global nutrition and pharmaceutical companies. Additionally, Clover Corporation invests in research and development to continuously innovate and expand its product offerings, further contributing to its earnings.

Clover Corporation Limited Financial Statement Overview

Summary

Clover Corporation Limited faces challenges with declining revenue and profitability, yet maintains a strong balance sheet and solid cash flow generation. The company's low leverage and high equity ratio offer stability, but declining ROE and margins are concerning. The ability to generate cash flow amidst decreasing profitability is a strength, but addressing top-line growth and margins is critical for future performance.

Income Statement

Clover Corporation Limited has experienced a significant decline in revenue and profitability over the past year. The gross profit margin decreased from 29.72% to 27.10%, and the net profit margin dropped from 7.77% to 2.44%. Revenue fell by 22.14% year-over-year, indicating challenges in maintaining sales. The EBIT margin also decreased from 12.47% to 5.03%. These metrics suggest pressure on both the top and bottom lines.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.15, reflecting conservative leverage. The equity ratio is high at 79.46%, indicating financial stability. However, ROE has decreased from 9.24% to 2.26%, which highlights a decline in profitability despite strong equity. Overall, the balance sheet suggests a sound financial position with low leverage but reduced returns on equity.

Cash Flow

Free cash flow increased by 20.19%, indicating improved cash generation despite declining revenue. The operating cash flow to net income ratio is robust at 5.58, demonstrating strong cash flow management. However, the free cash flow to net income ratio is at 4.04, which, while positive, reflects decreased net income. The cash flow statement shows resilience in cash generation amidst declining profitability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	72.49M	62.21M	79.88M	70.66M	60.51M	88.28M
Gross Profit	20.62M	16.86M	23.74M	21.66M	18.24M	29.71M
EBITDA	7.77M	3.98M	10.01M	11.01M	10.23M	19.04M
Net Income	4.53M	1.51M	6.21M	7.13M	6.00M	12.49M
Balance Sheet
Total Assets	81.44M	84.39M	86.20M	90.77M	78.73M	81.49M
Cash, Cash Equivalents and Short-Term Investments	15.38M	12.26M	9.44M	10.11M	9.09M	9.24M
Total Debt	6.03M	10.39M	11.71M	12.08M	14.19M	14.62M
Total Liabilities	13.49M	17.32M	19.05M	27.73M	20.32M	23.92M
Stockholders Equity	67.95M	67.07M	67.15M	63.04M	58.42M	57.57M
Cash Flow
Free Cash Flow	18.51M	6.13M	5.10M	4.51M	6.40M	6.11M
Operating Cash Flow	20.34M	8.45M	6.74M	5.93M	8.23M	6.66M
Investing Cash Flow	-2.42M	-2.97M	-2.53M	-1.43M	-1.83M	-4.02M
Financing Cash Flow	-10.60M	-2.66M	-4.88M	-3.49M	-6.55M	-1.67M

Clover Corporation Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CLV, the sentiment is Positive. The current price of 0.55 is below the 20-day moving average (MA) of 0.56, above the 50-day MA of 0.53, and above the 200-day MA of 0.46, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.51 is Neutral, neither overbought nor oversold. The STOCH value of 30.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CLV.

Clover Corporation Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLV	69 Neutral	AU$93.52M	20.66	6.80%	2.73%	15.48%	135.65%
Sector *	58 Neutral	HK$14.06B	4.84	-2.78%	5.73%	2.12%	-57.46%
F9H	―	€18.95M	―	-23.00%	―	―	―
HCT	57 Neutral	AU$33.50M	―		―	-5.86%	98.26%
NUC	48 Neutral	AU$24.89M	―	-47.74%	―	43.14%	51.35%
BUB	44 Neutral	AU$151.83M	―	-21.85%	―	30.54%	88.42%
NGS	31 Underperform	AU$3.70M	―		―	-16.29%	58.77%

Clover Corporation Limited Corporate Events

Clover Corporation Appoints New Director to Strengthen Leadership

Clover Corporation Limited has announced the appointment of Fiona Pearse as a new director, effective from August 1, 2025. This appointment is part of the company’s strategic efforts to strengthen its leadership team, although Fiona Pearse currently holds no securities or interests in the company. The announcement is expected to have implications for the company’s governance structure and could influence its strategic direction.

The most recent analyst rating on (AU:CLV) stock is a Buy with a A$0.60 price target. To see the full list of analyst forecasts on Clover Corporation Limited stock, see the AU:CLV Stock Forecast page.

Clover Corporation Announces Board Changes with New Appointment

Clover Corporation Limited has announced the appointment of Ms. Fiona Pearse as a Non-Executive Director, effective August 1, 2025, succeeding Mr. Graeme Billings, who will retire after 12 years of service. This strategic board succession aims to leverage Fiona’s extensive commercial expertise and leadership experience to strengthen Clover’s governance and support its growth ambitions.

The most recent analyst rating on (AU:CLV) stock is a Buy with a A$0.60 price target. To see the full list of analyst forecasts on Clover Corporation Limited stock, see the AU:CLV Stock Forecast page.

Clover Corporation Expects Strong FY25 Financial Performance

Clover Corporation Limited announced an expected outperformance in its unaudited Net Profit After Tax (NPAT) for FY25, surpassing market consensus by approximately 20%. The company’s full-year sales are also anticipated to exceed expectations, driven by a favorable product and customer mix, enhanced performance at Melody Dairies and Ecuador operations, and beneficial currency movements. CEO Peter Davey highlighted the strong contribution from Ecuador as a key factor in the company’s global production footprint, emphasizing the company’s robust balance sheet and continued momentum into FY26.

The most recent analyst rating on (AU:CLV) stock is a Buy with a A$0.60 price target. To see the full list of analyst forecasts on Clover Corporation Limited stock, see the AU:CLV Stock Forecast page.